The pulse rates during the atenolol treatment were all significantly lower than those during the methyldopa or non-atenolol periods (P < 0001).
Analysis of the questionnaire on side effects showed that the periods of treatment that incorporated methyldopa could be identified. More patients complained of dreams, increased sleeping, increased tiredness, and reduced energy after four weeks of treatment with methyldopa than during the three periods of treatment with chlorthalidone alone or the one period on atenolol alone.
Discussion
In patients with moderate hypertension on continuous treatment with chlorthalidone the addition of atenolol, methyldopa, or low doses of atenolol and methyldopa in combination is effective in reducing blood pressure. The fall in blood pressure with the addition of atenolol 150 mg/day was greater than that with methyldopa 750 mg/day.
The doses of atenolol chosen for study were adequate. In other studies we have shown that atenolol 50, 100, and 200 mg once daily2 or atenolol 200-400 mg/day, or in combination with bendrofluazide in twice daily doses,3 reduces raised blood pressures. In both these studies an increase in dose above the lowest dose did not further reduce mean blood pressure levels. This finding has been confirmed in the present study. Doubling the dose of methyldopa from 750 to 1500 mg/day did not increase the hypotensive effect significantly. This confirms the findings of Barritt et a14 and of Scott et al (personal communication).
The design of the study incorporated a run-in period and washout periods on chlorthalidone. The diuretic was included because in a previous study in a similar group of patients a period of treatment with placebo alone was included' and the mean levels of lying blood pressure during that placebo period were high-183/114 mm Hg (phase-4). Although we took the precaution of using a background diuretic we now believe that a lower initial dose of atenolol or methyldopa should have been used, because two patients on chlorthalidone had to be withdrawn from the study because of severe and symptomatic hypotension when the lower dose of each drug was added. effects in any way different from the parent compound. The 1-x-hydroxylated metabolites are used because in vitamin Dresistant disorders in which I-x-hydroxylation may be impaired (chronic renal failure, hypoparathyroidism, and vitamin D dependent rickets), it may be easier to achieve a therapeutic effect than with calciferol. Also the effective dose of the 1-7-hydroxylated derivatives, perhaps unlike calciferol, may not differ widely from patient to patient, and individual requirements may also change less abruptly.12 Finally, hypercalcaemia induced by these metabolites may be more readily reversed when treatment is stopped.
Introduction
Though some of these potential advantages remain to be proved, our results suggest that the toxic effects of vitamin D-like compounds may indeed be more readily reversed when the metabolites are used; and this mpore rapid reversal may be the major if not the sole advantage of these metabolites over vitamin D itself. Our results also illustrate the frequency with which hypercalcaemia occurred during long-term treatment with the 1-x-hydroxylated derivatives in chronic renal failure. Though seemingly unpredictable, this hypercalcaemia often occurred after several months of treatment for bone disease at which time bone turnover had been reduced (unpublished observations).
The rate of fall of plasma calcium after poisoning with vitamin D or its derivatives must be due to the reduction of vitamin D-like activity on the chief target organs, including the gut, kidney, and bone, which may each have a different relative importance in different diseases. The response may also depend on factors such as the length of treatment and the storage13 14 and metabolism of the agent given. For example, the loss of the ability to eliminate calcium through the kidneys in chronic renal failure may account for the slower return of plasma calcium than in normal subjects. In hypoparathyroidism the rate of return may depend more on the duration of the intestinal response.9 Under other conditions increased bone resorption may also contribute to sustained hypercalcaemia since it can be reversed rapidly with calcitonin (fig 4) . 
SHORT REPORTS Colour vision in vitamin A deficiency
Colour blindness is known to occur as a sex-linked genetic trait. A relatively high incidence of colour vision defects has been reported in patients with cirrhosis of liver.'--' Cruz-Coke postulated a common genetic basis for defective colour vision and cirrhosis,' while other workers have suggested that defective colour vision may be secondary to liver disease. Bronte-Steward and Foulds observed that in patients with biliary cirrhosis who had impaired dark adaptation and defective colour vision vitamin A treatment produced a significant improvement.:' It was suggested that these defects may be due to associated vitamin A deficiency. Vitamin A deficiency affects rod function with loss of dark adaptation, but little is known about the effect of hypovitaminosis A on cone function. We therefore investigated this point.
Patients, methods and results
Twenty-eight children, aged 4 to 12 years, with clinical signs of vitamin A deficiency were investigated. They showed conjunctival xerosis or Bitot spots, or both. Eighteen also had night blindness. The American Optical Hardy-Rand-Rittler (HRR) pseudoisochromatic plates were used to detect colour vision defects. Venous blood samples were obtained and serum 
Comment
Vitamin A deficiency is a major nutritional problem among children in many developing countries. The classical manifestations of vitamin A deficiency are night blindness, conjunctival xerosis, and Bitot spots. Severe deficiency of vitamin A, resulting in keratomalacia and total blindness, is seen mostly in preschool children.
It is generally agreed that serum vitamin A levels under 0 70
[smol/l (20 ,ug/100 ml) indicate vitamin A deficiency. In our study only those children who had serum vitamin A concentrations below 0 70 Humol/l were tested and colour vision was found to be normal in all. 
